- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Replimune Group Inc RP1 Program Update Call TranscriptDec 05, 2023
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Replimune Group Inc to Host Virtual Investor Event TranscriptDec 07, 2022
- Replimune Group Inc To Host Investor Day TranscriptMar 30, 2022
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Replimune Group Inc Annual Shareholders Meeting TranscriptSep 08, 2021
- Replimune Group Inc Virtual Investor Event Corporate Call TranscriptJun 03, 2021
- Replimune Group Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Replimune Group Inc to Provide Phase 1/2 Clinical Data Update on Patients with Melanoma and Non-Melanoma Skin Cancers - Conference Call TranscriptJun 03, 2020
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
&-
Let's get started here and welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is [Anupam Rama], I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, [Lorea Hall, and Malcolm Kuno]. Our next presenting company is Replimune presenting on behalf of the company, we have Philip Astley-Sparke. Philip?
Thank you, Anupam. Recognizing revenue and is an industry leader in oncolytic immunotherapy, we're progressing to asset RP1 and RP2 RP1. We plan to establish a broad skin cancer franchise in this regard, our foundational study is in PD-1 failed melanoma, where in 140 patient registrational cohort, we have shown benefit in approximately one in three patients by way of durable response and plan to file a BLA by the end of this year.
We've also generated data in multiple non-melanoma skin cancers, principally in cutaneous squamous cell carcinoma patients late
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)